BioNTech SE (NASDAQ:BNTX) Shares Purchased by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. boosted its stake in shares of BioNTech SE (NASDAQ:BNTX) by 207.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,583 shares of the company’s stock after purchasing an additional 1,743 shares during the quarter. PNC Financial Services Group Inc.’s holdings in BioNTech were worth $273,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in BNTX. FMR LLC increased its holdings in shares of BioNTech by 4.6% during the third quarter. FMR LLC now owns 237,844 shares of the company’s stock valued at $25,839,000 after purchasing an additional 10,422 shares during the period. Invesco Ltd. increased its stake in BioNTech by 7.4% during the 3rd quarter. Invesco Ltd. now owns 84,335 shares of the company’s stock valued at $9,162,000 after buying an additional 5,800 shares during the period. Federated Hermes Inc. raised its position in shares of BioNTech by 60.0% during the 3rd quarter. Federated Hermes Inc. now owns 8,000 shares of the company’s stock worth $869,000 after buying an additional 3,000 shares in the last quarter. O Shaughnessy Asset Management LLC lifted its stake in shares of BioNTech by 14.7% in the 3rd quarter. O Shaughnessy Asset Management LLC now owns 6,704 shares of the company’s stock worth $728,000 after acquiring an additional 857 shares during the period. Finally, AXQ Capital LP bought a new position in shares of BioNTech in the third quarter valued at approximately $304,000. 15.52% of the stock is currently owned by institutional investors.

BioNTech Trading Down 0.0 %

NASDAQ:BNTX opened at $80.36 on Monday. The stock has a market cap of $19.10 billion, a PE ratio of 160.72 and a beta of 0.27. BioNTech SE has a fifty-two week low of $80.02 and a fifty-two week high of $125.83. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.38 and a quick ratio of 11.16. The stock’s 50-day moving average is $92.22 and its two-hundred day moving average is $94.66.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Monday, May 6th. The company reported ($1.42) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.60). The company had revenue of $203.69 million for the quarter, compared to analyst estimates of $589.96 million. BioNTech had a return on equity of 0.55% and a net margin of 4.01%. As a group, equities research analysts forecast that BioNTech SE will post -2 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on BNTX. JPMorgan Chase & Co. cut their target price on BioNTech from $99.00 to $90.00 and set an “underweight” rating for the company in a research report on Friday, March 22nd. UBS Group decreased their target price on BioNTech from $110.00 to $101.00 and set a “neutral” rating for the company in a research note on Wednesday, March 27th. Canaccord Genuity Group reiterated a “buy” rating and issued a $171.00 price target on shares of BioNTech in a research report on Thursday, March 21st. TD Cowen raised their price objective on shares of BioNTech from $95.00 to $98.00 and gave the company a “hold” rating in a research report on Tuesday, May 7th. Finally, Evercore ISI initiated coverage on shares of BioNTech in a report on Tuesday, May 14th. They issued an “inline” rating and a $100.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have given a buy rating to the company. According to MarketBeat.com, BioNTech has an average rating of “Hold” and an average price target of $111.70.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.